← Back to Clinical Trials
Recruiting NCT06726941

NCT06726941 Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06726941
Status Recruiting
Phase
Sponsor Afyonkarahisar Health Sciences University
Condition Ischemic Stroke, Acute
Study Type INTERVENTIONAL
Enrollment 48 participants
Start Date 2024-12-20
Primary Completion 2026-06-09

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Physiotherapy and Rehabilitation Practices

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 48 participants in total. It began in 2024-12-20 with a primary completion date of 2026-06-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to demonstrate the effect of routine exercise program on neuroplasticity through histone acetylation and gene expression changes in acute stroke survivors from an epigenetic perspective and to investigate the correlation of epigenetic effects with its effects on motor function and quality of life.

Eligibility Criteria

Inclusion Criteria: 1. Participants who applied to Afyonkarahisar Health Sciences University Physical Therapy and Rehabilitation Clinic for rehabilitation purposes and had a stroke for the first time 2. Participants with ischemia as the etiology of stroke 3. Participants between the ages of 25-70 4. Drugs that have been used for at least 1 month and up to 6 months after a cerebrovascular accident Exclusion Criteria: 1. Participants whose stroke etiology is other than ischemia 2. Participants with clinically significant neurological disease other than stroke 3. Participants with systemic and musculoskeletal diseases that will not tolerate neurological rehabilitation and prevent them from participating

Contact & Investigator

Central Contact

Hasan Toktaş, Professor

✉ hasantoktas@yahoo.com

📞 +905052212901

Principal Investigator

Hasan Toktas, Professor

PRINCIPAL INVESTIGATOR

Afyonkarahisar Health Sciences University

Frequently Asked Questions

Who can join the NCT06726941 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 70 Years, studying Ischemic Stroke, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06726941 currently recruiting?

Yes, NCT06726941 is actively recruiting participants. Contact the research team at hasantoktas@yahoo.com for enrollment information.

Where is the NCT06726941 trial being conducted?

This trial is being conducted at Afyonkarahisar, Turkey (Türkiye).

Who is sponsoring the NCT06726941 clinical trial?

NCT06726941 is sponsored by Afyonkarahisar Health Sciences University. The principal investigator is Hasan Toktas, Professor at Afyonkarahisar Health Sciences University. The trial plans to enroll 48 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology